Drug General Information (ID: DDI49VL6GU)
Drug Name			Mefenamic acid		Drug Info		Pralatrexate		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiinflammatory Agents				Antimetabolites
Structure

Mechanism of Mefenamic acid-Pralatrexate Interaction (Severity Level: Moderate)
Decreased renal excretion (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Mefenamic acid				Pralatrexate
Mechanism		Competitive inhibition of renal excretion of pralatrexate				Pralatrexate
Key Mechanism Factor 1
		Factor Name		Pharmacokinetics
		Factor Description		Alters the excretion of the drug, resulting in changes in the plasma concentration of the drug and affecting the pharmacological effects.
Mechanism Description		Decreased renal excretion of Pralatrexate caused by Mefenamic acid

Recommended Action
Management		Caution is advised if pralatrexate is prescribed in combination with trimethoprim/sulfamethoxazole or NSAIDs. Complete blood cell counts as well as renal and hepatic function should be closely monitored. Treatment interruption or dose reduction of pralatrexate may be required if toxicities such as mucositis, myelosuppression, or liver enzyme abnormalities develop. Patients should be advised to contact their physician if they develop oral ulcers, painful swallowing, vomiting, diarrhea, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.

References
1	Product Information. Folotyn (pralatrexate). Allos Therapeutics, Westminster, CO.